Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

ical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment Review (752) Total Article Views Authors: Pefura Yone EW, Kengne AP Published Date December 2012 Volume 2012:4 Pages 181 - 184 DOI: http://dx.doi.org/10.2147/HIV.S24432 Received: 02 October 2012 Accepted: 16 November 2012 Published: 05 December 2012 Eric W Pefura Yone,1,2 André P Kengne3 1Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon; 2Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, Cameroon; 3South African Medical Research Council and University of Cape Town, Cape Town, South Africa Abstract: An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients’ adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.